Results 41 to 50 of about 34,859 (234)

The V_H repertoire and clonal diversification of B cells in inflammatory myopathies [PDF]

, 2014
The contribution of antigen-driven B-cell adaptive immune responses within the inflamed muscle of inflammatory myopathies (IMs) is largely unknown.
Field, Max, McIntyre, Donna, Mehr, Ramit, Stott, David I., Zuckerman, Neta S.   +4 more
core   +1 more source

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers

Respirology Case Reports, 2021
We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and ...
Ryosuke Imai, Sumie Ikemura, Torahiko Jinta   +2 more
doaj   +1 more source

Inclusion body myositis: therapeutic approaches. [PDF]

, 2012
The idiopathic inflammatory myopathies are a heterogeneous group of diseases that include dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and other less common myopathies.
Aggarwal, Rohit, Oddis, Chester V
core   +1 more source

Small cell lung cancer with dermatomyositis: a case report

Frontiers in Oncology
Dermatomyositis represents an autoimmune disorder characterized by notable skin and muscular manifestations. The annual incidence of dermatomyositis stands at approximately (5~10)/1 million individuals.
Xiaomin Guan, Shi Qiu, Yinghui Xu, Jianjiao Zu, Chao Sun, Ye Guo, Xu Wang, Kewei Ma   +7 more
doaj   +1 more source

An unusual presentation of a case of human psittacosis [PDF]

, 2018
Background: Chlamydia psittaci is a gram-negative, obligate intracellular organism. Birds are the main reservoir, but also non-avian domestic animals and humans can be infected.
Boelens, Jerina, De Spiegeleer, Anton, Thijs, Elke, Van Braeckel, Eva, Vande Weygaerde, Yannick, Vanrompay, Daisy, Vermaelen, Karim, Versteele, Charlot   +7 more
core   +3 more sources

Dermatomyositis with Kaposi’s Sarcoma in a Patient without Human Immunodeficiency Virus-1 Infection

Canadian Journal of Gastroenterology, 1991
The first case of dermatomyositis complicating cutaneous and visceral Kaposi’s sarcoma is presented in a 75-year-old man without human immunodeficiency virus infection.
Dana Liang, Andrew Szilagyi, Robin C Billick, Herbert Srolovitz, Ricardo Bullen   +4 more
doaj   +1 more source

Dermatomyositis and Malignancy

Journal of Investigative Dermatology, 1993
During the past 12 years, many studies applying strict diagnostic criteria have been published that have attempted to settle the controversy about the reality of the association between dermatomyositis and malignancy. Although retrospective, recent studies have shown an increased incidence of malignancy among patients with dermatomyositis when compared
Jean-Marie Bonnetblanc, Philippe Bernard
openaire   +3 more sources

Dermatomyositis and HIV [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2016
HIV has been linked to several autoimmune disorders since its emergence in the 1980s. By affecting different cells and pathways in the immune system, HIV induces the development of certain autoimmune diseases while prohibiting the emergence of others. Dermatomyositis has been rarely described in patients with HIV.
Jeffrey Lederman, Mamata Chand, Kristine Sarmosyan, Stephen Jesmajian, Karen M. Weidenheim, Ashutossh Naaraayan   +5 more
openaire   +4 more sources

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report

JTO Clinical and Research Reports, 2021
SCLC is frequently associated with paraneoplastic syndromes, including dermatomyositis. Patients with malignancy-associated dermatomyositis express a specific autoantibody pattern usually positive for anti–transcription intermediary factor 1-γ (TIF1-γ ...
Johnathan Arnon, MD, Anna Elia, MD, Yuval Nevo, PhD, Alexander Lossos, MD, Hovav Nechushtan, MD, PhD   +4 more
doaj  

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source